{"id":828880,"date":"2025-03-24T08:11:24","date_gmt":"2025-03-24T12:11:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/"},"modified":"2025-03-24T08:11:24","modified_gmt":"2025-03-24T12:11:24","slug":"windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/","title":{"rendered":"Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WARRINGTON, Pa., March  24, 2025  (GLOBE NEWSWIRE) &#8212; Windtree Therapeutics, Inc. (\u201cWindtree\u201d or the \u201cCompany\u201d) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that the Company received notice from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) that Windtree has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. The Company will be subject to a mandatory panel monitor until March 20, 2026.<\/p>\n<p>The Company was previously notified by Nasdaq on December 4, 2024 that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive trading days, as required by the Nasdaq Listing Rules. To regain compliance with the rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. Nasdaq noted that this requirement was met and had been exhibited by a closing bid price of more than $1.00 since February 21, 2025.<\/p>\n<p>\n        <strong>About Windtree Therapeutics, Inc.<br \/><\/strong>Windtree Therapeutics, Inc. is a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree\u2019s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong><br \/>\n        <br \/>This press release contains statements related to the potential clinical effects of istaroxime; the potential benefits and safety of istaroxime; and the clinical development of istaroxime. Such statements constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of future events or outcomes to identify forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company\u2019s current expectations. Examples of such risks and uncertainties include, among other things: the Company\u2019s ability to acquire revenue generating subsidiaries; the market\u2019s reaction to potential acquisitions by the Company; the Company\u2019s ability to secure significant additional capital as and when needed; the Company\u2019s ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company\u2019s risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company\u2019s other product candidates, including preclinical oncology candidates; the Company\u2019s ability to access the debt or equity markets; the Company\u2019s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company\u2019s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company\u2019s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company\u2019s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company\u2019s product candidates, and the Company\u2019s ability to service those markets; the Company\u2019s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company\u2019s product candidates, if approved; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People\u2019s Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and\/or other countries which could have an adverse impact on the Company\u2019s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company\u2019s ability to access the capital markets. These and other risks are described in the Company\u2019s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.\u00a0<\/p>\n<p>\n        <strong>Contact Information:<\/strong>\n      <\/p>\n<p>Eric Curtis<br \/>ecurtis@windtreetx.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTMyOSM2ODE4ODU0IzUwMDA3MzYyMA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDBmZTc3YTctNjhiZS00NTQ3LTk1YjUtZTIxYmRlNzdlYjAxLTUwMDA3MzYyMC0yMDI1LTAzLTI0LWVu\/tiny\/Windtree-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) &#8212; Windtree Therapeutics, Inc. (\u201cWindtree\u201d or the \u201cCompany\u201d) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that the Company received notice from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) that Windtree has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. The Company will be subject to a mandatory panel monitor until March 20, 2026. The Company was previously notified by Nasdaq on December 4, 2024 that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-828880","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) &#8212; Windtree Therapeutics, Inc. (\u201cWindtree\u201d or the \u201cCompany\u201d) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that the Company received notice from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) that Windtree has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. The Company will be subject to a mandatory panel monitor until March 20, 2026. The Company was previously notified by Nasdaq on December 4, 2024 that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing &hellip; Continue reading &quot;Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-24T12:11:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTMyOSM2ODE4ODU0IzUwMDA3MzYyMA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules\",\"datePublished\":\"2025-03-24T12:11:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\\\/\"},\"wordCount\":987,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTMyOSM2ODE4ODU0IzUwMDA3MzYyMA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\\\/\",\"name\":\"Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTMyOSM2ODE4ODU0IzUwMDA3MzYyMA==\",\"datePublished\":\"2025-03-24T12:11:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTMyOSM2ODE4ODU0IzUwMDA3MzYyMA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTMyOSM2ODE4ODU0IzUwMDA3MzYyMA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/","og_locale":"en_US","og_type":"article","og_title":"Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules - Market Newsdesk","og_description":"WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) &#8212; Windtree Therapeutics, Inc. (\u201cWindtree\u201d or the \u201cCompany\u201d) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that the Company received notice from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) that Windtree has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. The Company will be subject to a mandatory panel monitor until March 20, 2026. The Company was previously notified by Nasdaq on December 4, 2024 that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing &hellip; Continue reading \"Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-24T12:11:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTMyOSM2ODE4ODU0IzUwMDA3MzYyMA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules","datePublished":"2025-03-24T12:11:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/"},"wordCount":987,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTMyOSM2ODE4ODU0IzUwMDA3MzYyMA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/","name":"Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTMyOSM2ODE4ODU0IzUwMDA3MzYyMA==","datePublished":"2025-03-24T12:11:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTMyOSM2ODE4ODU0IzUwMDA3MzYyMA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTMyOSM2ODE4ODU0IzUwMDA3MzYyMA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-regains-compliance-with-nasdaq-listing-rules\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=828880"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828880\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=828880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=828880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=828880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}